Ovarian Cancer Industry, March 2015 Market Reports from Top Publishers

You might be interested in: cancer, medical equipment, therapeutics, breast cancer, cancer drug, drug, oncology, aids, biomarker, cancer testing, diagnostic, plc, sarcoma, stem cell.


 
1-10 of about 100 reports for Ovarian Cancer

Therapeutics for ”Silent” Cancers

Therapeutics for ”Silent” Cancers

  • $ 6 650
  • Industry report
  • February 2015
  • by BCC Research

REPORT HIGHLIGHTS The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual ...

Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across ...

Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed ...

Global Pharma US & EU Outlook 2015  : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

Global Pharma US & EU Outlook 2015 : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

  • $ 2 000
  • Industry report
  • January 2015
  • by MP Advisors

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several ...

Mature Biotech  Outlook 2015: New Therapy Ventures Pave the Way for Success

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

  • $ 2 000
  • Industry report
  • January 2015
  • by MP Advisors

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies ...

Ovarian Cancer Drug Pathway Analyzer 2015

Ovarian Cancer Drug Pathway Analyzer 2015

  • $ 2 249
  • Industry report
  • January 2015
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 349 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways ...

Aposense Ltd. (Symbol:APOS) SWOT Analysis, Strategy, Revenues and Profits

Aposense Ltd. (Symbol:APOS) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

OXiGENE, Inc. (Symbol:OXGN) SWOT Analysis, Strategy, Revenues and Profits

OXiGENE, Inc. (Symbol:OXGN) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

Viralytics Ltd. (Symbol:VLA) SWOT Analysis, Strategy, Revenues and Profits

Viralytics Ltd. (Symbol:VLA) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

About 1 000 reports for Ovarian Cancer

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • August 2014
    25 pages
  • Cancer  

    Breast Cancer  

  • United States  

View report >

1 Companies for Ovarian Cancer

Read our Company Profiles

Eli Lilly and Co.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.